British and US Reports Show Increased Fatal Risks With Yaz

U.S. health regulators are still worried about the potential for Yaz and Yasmin blood clots posed by the drospirenone-containing birth control pills. In a Drug Safety Communication posted on its website yesterday, the U.S. Food & Drug Administration (FDA) said preliminary results of an agency-funded study suggest women who use Yaz, Yasmin and other oral contraceptives made with drospirenone could face a 1.5-fold increase in the risk of blood clots compared to those who take other pills. More recently, two articles published in 2011 in the British Medical Journal reported a 2- to 3-fold greater risk of blood clots in women using oral contraceptives containing drospirenone rather than levonorgestrel.  Yasmin and Yaz have also been linked to Yaz heart attack, DVT, and stroke.

Yaz Settlement Promised to be Requested After Bellwether Trials

More than 6,300 lawsuits are currently pending in the Yaz and Yasmin lawsuits have combined to form a multidistrict litigation before Judge Herndon. In October 2010, a Case Management Order was established in the federal MDL, scheduling three Yaz and Yasmin bellwether trials, which are representative cases that will be used to gauge how juries will respond to testimony and evidence that is likely to be introduced throughout other cases in the litigation. The first trial was scheduled to begin in September 2011, involving a Yaz pulmonary embolism lawsuit, followed by a second

Chemicals in Yaz Shown to Cause Hyperkalemia by FDA

Yaz (drosperinone & ethinyl estradiol) is a once-a-day birth control pill that was first approved by the FDA in March 2006 to prevent unwanted pregnancy. Drospirenone can increase blood potassium levels, known as hyperkalemia, which can result in the Yaz heart problems and other Yaz side effects. Individuals who have pre-existing kidney, liver and adrenal disease could be particularly susceptible. The judge presiding over every federal Yaz lawsuit and Yasmin lawsuit has declined to consolidate multiple cases during the early bellwether trials,

Judge In Yaz MDL Announces Hopes For Settlements to Occur

In October 2010, Judge Herndon implemented a process that calls for a handful of cases to be prepared for a series of three early trials, known as bellwether cases. The first trial will involve a Yaz pulmonary embolism. The second trial will involve a gallbladder injury from Yaz and the third trial will involve a venous thromboembolism (VTE), such as a deep vein thrombosis (DVT). Currently the Yasmin and Yaz lawsuits have been centralized for pretrial proceedings in the federal court system as well as several states. In federal court, all cases filed throughout the country are being handled out of the U.S. District Court for the Southern District

British and US Reports Show Increased Fatal Risks With Yaz

U.S. health regulators are still worried about the potential for Yasmin and Yaz blood clots posed by the drospirenone-containing birth control pills. In a Drug Safety Communication posted on its website yesterday, the U.S. Food & Drug Administration (FDA) said preliminary results of an agency-funded study suggest women who use Yaz, Yasmin and other oral contraceptives made with drospirenone could face a 1.5-fold increase in the risk of blood clots compared to those who take other pills. More recently, two articles published in 2011 in the British Medical Journal reported a 2- to 3-fold greater risk of blood clots in women using oral contraceptives containing drospirenone rather than levonorgestrel.

Complaints have been filed on behalf of women who have suffered heart attacks, strokes, Yaz pulmonary embolism, deep vein thrombosis and other

Yaz Pulmonary Embolism: Grounds for a Lawsuit

Around 190 women may have died of an apprent result of side effects of Yaz and Yasmin, the Brand name drospirenone-based birth control pills as well as the generic form marketed as Ocella. These three types are the only birth control pills that contain the synthetic hormone drospirenone. They also contain an amount of estrogen, commonly found in other forms of hormonal birth control.

            Scientists have long known that there is a risk of blood clots associated with any form of hormonal birth control due to the amount of estrogen in the drugs. However, scientific studies have shown that users of pills with drospirenone in them have their risk for  Yaz blood clots increased by 6.3 percent. Yaz has been linked to many conditions, and pulmonary embolism and deep vein thrombosis,  also known as DVT, are some of the most serious. Both conditions are related to blood clots and can be fatal if not treated properly and quickly.

          Yaz DVT occurs when